A homogeneous treatment for non-DIPG diffuse midline glioma. Issue 3 (June 2023)

• Record Type: Journal Article
• Authors: Schiavello, Elisabetta; Biassoni, Veronica; Gattuso, Giovanna; Podda, Marta; Chiaravalli, Stefano; Barretta, Francesco; Antonelli, Manila; De Cecco, Loris; Pecori, Emilia; Gandola, Lorenza; Massimino, Maura
• Is Part Of: Tumori. Volume 109:Issue 3(2023)
• Page Start: 269
• Page End: 275
• Publication Date: 2023-06
• Subjects: Diffuse midline glioma -- radiotherapy -- nimotuzumab -- vinorelbine -- p53; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916221099067
• Languages: English
• ISSNs: 0300-8916

Abstract

Introduction: The H3K27M-mutant diffuse midline glioma (DMG) was first included in the World Health Organization (WHO) Classification of central nervous system (CNS) tumors in 2016, and confirmed in its fifth edition. The biological behavior and dismal prognosis of this tumor resemble diffuse intrinsic pontine gliomas (DIPG). Homogeneously-treated series are rarely reported. Methods: From 2016 onwards, we treated patients with DMG with radiotherapy and concomitant/adjuvant nimotuzumab/vinorelbine, plus re-irradiation at relapse, as already done for DIPG. Results: We treated nine patients, seven females, with a median age at diagnosis of 13 years. Tumor sites were: thalamic in five cases, pontocerebellar in two, pineal in one, and paratrigonal with nodular/leptomeningeal dissemination in one. Three patients were biopsied, and six had partial tumor resections. Central pathological review was always performed. The median time to local progression was 12.7 months, and the median overall survival was 17.8 months. Six patients died of tumor progression, one of cerebral bleeding at progression. Two were alive, one in continuous remission, the other after relapsing, at 38.6 and 46.3 months after diagnosis. Progression-free survival was 33.3% at one year. Overall survival was 88.9%, 33.3% and 22.2% at 1, 2 and 3 years, respectively. Conclusions: This is a small series of homogeneously-treated DMG patients. The results obtained are comparable with those of DIPG patients. Given the phenotypically- and molecularly-defined setting of DMG and severe outcome in this orphan population, they should be treated and included in registries and protocols of DIPG.